Cargando…

Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19

(1) Background: Cirrhotic patients have an increased risk for severe COVID-19. We investigated the renin-angiotensin-aldosterone system (RAS), parameters of endothelial dysfunction, inflammation, and coagulation/fibrinolysis in cirrhotic patients and in COVID-19 patients. (2) Methods: 127 prospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartl, Lukas, Jachs, Mathias, Simbrunner, Benedikt, Bauer, David J. M., Semmler, Georg, Gompelmann, Daniela, Szekeres, Thomas, Quehenberger, Peter, Trauner, Michael, Mandorfer, Mattias, Scheiner, Bernhard, Reiberger, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709210/ https://www.ncbi.nlm.nih.gov/pubmed/34945736 http://dx.doi.org/10.3390/jpm11121264

Ejemplares similares

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

An impaired pituitary–adrenal signalling axis in stable cirrhosis is linked to worse prognosis
por: Hartl, Lukas, et al.
Publicado: (2023)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis
por: Hofer, Benedikt S., et al.
Publicado: (2022)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis
por: Bucsics, Theresa, et al.
Publicado: (2022)

Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites
por: Thaler, Johannes, et al.
Publicado: (2021)

The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation
por: Hartl, Lukas, et al.
Publicado: (2023)

Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression
por: Jachs, Mathias, et al.
Publicado: (2022)

COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality
por: Hartl, Lukas, et al.
Publicado: (2021)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
por: Hartl, Lukas, et al.
Publicado: (2021)

Age‐adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID‐19 patients
por: Hartl, Lukas, et al.
Publicado: (2022)

Gut-liver axis signaling in portal hypertension
por: Simbrunner, Benedikt, et al.
Publicado: (2019)

Recent advances in the understanding and management of hepatorenal syndrome
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2022)

Imaging features facilitate diagnosis of porto-sinusoidal vascular disorder
por: Lampichler, Katharina, et al.
Publicado: (2022)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event
por: Balcar, Lorenz, et al.
Publicado: (2022)

Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata
por: Hartl, Lukas, et al.
Publicado: (2022)

Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic
por: Hartl, Lukas, et al.
Publicado: (2022)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease
por: Hartl, Lukas, et al.
Publicado: (2022)

Non-invasive tests-based risk stratification: Baveno VII and beyond
por: Semmler, Georg, et al.
Publicado: (2023)

The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2020)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Outcomes of an HCV elimination program targeting the Viennese MSM population
por: Jachs, Mathias, et al.
Publicado: (2021)

Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension
por: Raeven, Pierre, et al.
Publicado: (2020)

Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Endoscopic band ligation is safe despite low platelet count and high INR
por: Pfisterer, Nikolaus, et al.
Publicado: (2023)

Transferrin as a predictor of survival in cirrhosis
por: Viveiros, André, et al.
Publicado: (2018)

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital
por: Pomej, Katharina, et al.
Publicado: (2021)

Portal hypertensive gastropathy is associated with iron deficiency anemia
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h0rscffvo9r7d9q50m3b4h4f9s